6533b7d4fe1ef96bd1262a5d

RESEARCH PRODUCT

Cancer of the Thyroid

Alfredo BerrutiLorena IncorvaiaValerio GristinaNadia BarracoSilvio Buscemi

subject

OncologySorafenibmedicine.medical_specialtyCabozantinibbusiness.industrySettore MED/06 - Oncologia MedicaThyroidVandetanibmedicine.diseaseSettore MED/13 - EndocrinologiaThyroid carcinomaThyroid cancer classification diagnosischemistry.chemical_compoundmedicine.anatomical_structurechemistryInternal medicineEndocrine neoplasmmedicineSettore MED/49 - Scienze Tecniche Dietetiche ApplicateLenvatinibbusinessThyroid cancermedicine.drug

description

Thyroid cancers are the most frequent endocrine neoplasms whose incidence is globally increasing. Thyroid carcinomas basically derived from follicular (papillary, follicular, anaplastic and poorly differentiated) or parafollicular cells (medullary). The diagnostic evaluation of thyroid cancers is mainly based on neck ultrasonography along with fine needle aspiration. First initial risk evaluation should be carried out postoperatively, while a dynamic risk stratification should be continually assessed to personalize treatment. Whereas combination of surgery, adjuvant radioactive iodine (RAI) ablation, and hormone therapy enables high rates of cure in differentiated tumors (DTC), surgical resection may represent the only definitive therapy in medullary (MTC) and poorly differentiated cancers. International regulatory agencies have recently approved targeted therapy for iodine refractory-DTC (sorafenib and lenvatinib) and for progressive or metastatic MTC (cabozantinib and vandetanib).

yearjournalcountryeditionlanguage
2021-10-07
10.1007/978-3-030-56051-5_56http://hdl.handle.net/10447/525818